SBIO
·ARCA
--
--(--)
--
--(--)
Key Stats
Assets Under Management
119.36MUSD
Fund Flows (1Y)
-24.31MUSD
Dividend Yield
2.33%
Discount/Premium to NAV
0.13%
Shares Outstanding
2.35M
Expense Ratio
0.50%
About ALPS Medical Breakthroughs ETF
Issuer
ALPS Advisors, Inc.
Brand
ALPS
Inception Date
Dec 30, 2014
Structure
Open-Ended Fund
Index Tracked
S-Network Medical Breakthroughs Index
Management Style
Passive
Dividend Treatment
Distributes
Distribution Tax Treatment
Qualified dividends
Income Tax Type
Capital Gains
Max ST Capital Gains Rate
39.60%
Max LT Capital Gains Rate
20.00%
Primary Advisor
ALPS Advisors, Inc.
Distributor
ALPS Portfolio Solutions Distributor, Inc.
SBIO invests in a concentrated portfolio of biotech companies with drugs in Phase II and Phase III of U.S. Food and Drug Administration (FDA) clinical trials, and limits itself to US-listed firms with market caps between USD 200 million and USD 5 billion. SBIO also screens for sustainability, meaning constituent firms have enough cash on hand to last two years. Given the low historical success rates in clinical trials, the fund is a high-risk, high-reward bet on a small subset of biotech companies. The Underlying Index undergoes semi-annual reconstitution and quarterly rebalance subject to certain caps. The largest stock is capped at 4.5%, and the excess weight is redistributed proportionately over the remainder of the Underlying Index. Prior to July 9, 2019 the fund's index was Poliwogg Medical Breakthroughs Index, which has the same strategies.
Classification
Asset Class
Equity
Category
Sector
Focus
Health Care
Niche
Biotechnology
Strategy
Fundamental
Geography
U.S.
Weighting Scheme
Market Cap
Selection Criteria
Fundamental
Returns
1-Month | 3-Month | YTD | 1-Year | 3-Year | 5-Year | |
|---|---|---|---|---|---|---|
Price Performance | +9.74% | +40.63% | +51.95% | +42.62% | +72.30% | -5.89% |
NAV Total Return | +10.40% | +37.77% | +53.63% | +39.00% | +77.34% | +1.73% |
Ratings
No data is currently available
Ainvest’s AI-powered ETF Scoring Algorithm, built to help retail investors make smarter, data-driven decisions. Leveraging deep learning, reinforcement learning, and large language models, the algorithm scores ETFs across five key dimensions: Fund Flow, Momentum, Safety, Fundamentals, and Performance. Each factor is weighted by its correlation to future returns, resulting in a single, actionable score. Backtested over five years with consistently strong predictive accuracy. Ainvest brings institutional-grade artificial intelligence to everyday investors—transforming complexity into clarity with every score.
Holdings Analysis
Sector
Healthcare
100.00%
Healthcare
100.00%
Asset
Region
92.57%
6.51%
0.92%
Category
Ratio
North America
92.57%
Europe
6.51%
Asia
0.92%
Investment Style
Mega
Large
Medium
Multi
Small
Value
Blend
Growth
Small-Cap Growth
Focuses on small-cap companies expected to grow substantially. These ETFs invest in emerging firms with robust growth trajectories.
Top 10 Holdings
Symbol
Ratio
RNA
Avidity Biosciences
4.43%
ARWR
Arrowhead Pharmaceuticals
4.00%
RYTM
Rhythm
3.28%
AXSM
Axsome Therapeutics
3.16%
CYTK
Cytokinetics
3.14%
MRUS
Merus
2.99%
KRYS
Krystal Biotech
2.86%
NUVL
Nuvalent
2.83%
PRAX
Praxis
2.46%
PTCT
Ptc Therapeutics
2.44%
Top 10 Weight 31.59%
102 Total Holdings
Dividends
Dividend Payout History
Declaration Date | Record Date | Payment Date | Amount |
|---|---|---|---|
| 2024-12-19 | 2024-12-19 | 2024-12-26 | 1.173 |
| 2023-12-21 | 2023-12-22 | 2023-12-27 | 0.071 |
| 2019-12-19 | 2019-12-20 | 2019-12-27 | 0.016 |
| 2018-12-20 | 2018-12-21 | 2018-12-27 | 0.784 |
| 2017-12-21 | 2017-12-22 | 2017-12-28 | 0.580 |
Premium/Discount Chart
Premium/Discount to NAV
Price
1M
Assets Under Management
Assets Under Management
1M
Fund Flows
Inflows
Outflows
1M
